Investment Thesis
Celularity is in critical financial distress with negative stockholders' equity of -$20.1M, liabilities exceeding assets by $20.1M, and severe liquidity constraints (0.16x current ratio). Despite 138% revenue growth, the company is burning cash at an unsustainable rate (-$8.3M FCF) with massive operating losses (-$39.2M) that dwarf gross profits, indicating fundamental business model challenges in its pharmaceutical operations.
Strengths
- Strong revenue growth of 138% year-over-year showing market demand
- Positive gross margin of 30.1% indicating viable unit economics at the product level
- Improved diluted EPS by 76% YoY despite continued losses, suggesting cost structure improvements
Risks
- Negative stockholders' equity of -$20.1M indicates technical insolvency and imminent need for capital restructuring or dilutive financing
- Critical liquidity crisis with only $120K cash against $134.3M liabilities and 0.16x current ratio, unable to fund operations or debt obligations
- Operating losses of -$39.2M far exceed gross profits, signaling unsustainable R&D, SG&A, and operating expenses despite revenue scaling
- Negative free cash flow of -$8.3M with -37% FCF margin indicates cash burn model is not sustainable without external funding
- $35.7M long-term debt burden with zero interest coverage capability given operating losses
Key Metrics to Watch
- Cash balance and runway until insolvency without additional financing
- Path to operating profitability and timeline to positive operating cash flow
- Debt restructuring plans or additional capital raises and dilution impact
- Revenue growth sustainability and gross margin maintenance as company scales
Financial Metrics
Revenue
22.4M
Net Income
-67.4M
EPS (Diluted)
$-2.74
Free Cash Flow
-8.3M
Total Assets
114.2M
Cash
120.0K
Profitability Ratios
Gross Margin
30.1%
Operating Margin
-174.9%
Net Margin
-300.1%
ROE
N/A
ROA
-59.0%
FCF Margin
-37.0%
Balance Sheet & Liquidity
Current Ratio
0.16x
Quick Ratio
0.12x
Debt/Equity
N/A
Debt/Assets
117.6%
Interest Coverage
N/A
Long-term Debt
35.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T04:06:11.319801 |
Data as of: 2025-09-30 |
Powered by Claude AI